Advertisement Theregen completes enrollment for Anginera safety trial - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Theregen completes enrollment for Anginera safety trial

Theregen has completed enrollment of a 15-patient Phase I safety trial for its Anginera epicardial patch on patients undergoing coronary arterial bypass graft surgery.

Millipore expects the new facility will employ 120 before the end of 2009. The company currently employs over 1,000 in Massachusetts and almost 6,000 around the world.

Millipore’s Mobius FlexReady Solutions are made up of single-use assemblies (Flexware) and process-ready hardware systems optimized for clarification, media and buffer preparation, tangential flow filtration (TFF) and virus filtration unit operations.

“The opening of our Danvers manufacturing facility is positive not only for Millipore, but for the state of Massachusetts as well,” said Millipore chairman, president and chief executive officer Martin Madaus. “We made a decision to move manufacturing of this product line from California and bring it to Massachusetts, which will mean additional jobs in the state, not to mention an exciting, innovative technology that is already having an impact on biopharmaceutical manufacturing.”